| abstract |
The present invention provides methods for predicting whether or not a test subject having primary biliary cholangitis (PBC) will benefit from advanced treatment in the form of a second- line agent used in addition to, or as an alternative to, ursodeoxycholic acid (UDCA). Associated methods for determining the therapeutic effect of a treatment regimen for PBC, methods for monitoring PBC progression, methods of PBC treatment, kits and assay devices are also provided. |